Kymera Therapeutics presents KT-621 clinical data for atopic dermatitis
KYMR•Kymera Therapeutics completed enrollment in its KT-621 Phase 2b atopic dermatitis trial, with data expected by year-end 2026. The company plans to begin Phase 3 trials by mid-2027, six months ahead of schedule for the program.
1. Atopic dermatitis trial
Kymera Therapeutics completed enrollment in its KT-621 Phase 2b atopic dermatitis trial and expects data by year-end 2026. Phase 3 trials are planned to begin by mid-2027, with the program six months ahead of schedule.
2. Other program updates
The ongoing KT-621 Phase 2b asthma trial is expected to report data in late 2027. Earlier Phase 1b results showed a 63% mean EASI reduction, with no serious or severe adverse events. Kymera said its oral IRF5 degrader KT-579 is scheduled to enter the LUMORA Phase 1b lupus trial by early 2027.
